Brokers expect Xeris Biopharma Holdings, Inc. (NASDAQ:XERS – Get Rating) to record sales of $25.47 million for the current fiscal quarter, reports Zacks Investment Research. Four analysts have released earnings estimates for Xeris Biopharma. The lowest sales estimate is $24.69 million and the highest is $27.20 million. Xeris Biopharma reported sales of $8.84 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 188.1%. The company is expected to announce its next quarterly results on Monday, January 1.
On average, analysts expect Xeris Biopharma to report annual revenue of $109.97 million for the current fiscal year, with estimates ranging from $103.00 to $117.90 million. For the next fiscal year, analysts expect the company to post sales of $158.63 million, with estimates ranging from $136.00 million to $192.40 million. Zacks Investment Research sales averages are an average average based on a survey of sell-side analysts who follow Xeris Biopharma.
Xeris Biopharma (NASDAQ:XERS – Get Rating) last reported results on Thursday, March 10. The company reported ($0.42) earnings per share for the quarter, missing analyst consensus estimates of ($0.21) by ($0.21). Xeris Biopharma posted a negative return on equity of 258.57% and a negative net margin of 217.81%. The company posted revenue of $21.43 million in the quarter, compared to $20.72 million expected by analysts. During the same period last year, the company posted ($0.41) EPS.
Several analysts have commented on XERS shares. Craig Hallum assumed Xeris Biopharma stock coverage in a Thursday, April 28, research report. They set a “buy” rating and a price target of $6.50 for the company. SVB Leerink lowered its price target on Xeris Biopharma from $8.00 to $6.00 and set an “outperform” rating on the stock in a Wednesday, February 16 research report. Zacks Investment Research upgraded Xeris Biopharma from a “sell” rating to a “hold” rating in a Thursday, May 19 report. HC Wainwright reissued a “buy” rating and set a target price of $6.00 (down from $8.00 previously) on Xeris Biopharma shares in a Friday, March 11 research note. Finally, Mizuho reduced its price target on Xeris Biopharma shares from $8.00 to $6.00 and set a “buy” rating on the stock in a Wednesday, March 16 research note. One equity research analyst gave the stock a hold rating and four gave the company’s stock a buy rating. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $6.13.
In other news, insider Paul R. Edick bought 100,000 shares in a trade dated Thursday, May 12. The shares were purchased at an average cost of $1.40 per share, for a total transaction of $140,000.00. Following the transaction, the insider now owns 1,508,064 shares of the company, valued at $2,111,289.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available on the SEC’s website. 4.01% of the shares are currently held by insiders of the company.
Several hedge funds and other institutional investors have recently bought and sold shares of the company. Virtu Financial LLC acquired a new stake in shares of Xeris Biopharma in the first quarter worth $131,000. Royal Bank of Canada increased its stake in Xeris Biopharma by 115.9% during the first quarter. Royal Bank of Canada now owns 43,405 shares of the company worth $111,000 after purchasing an additional 23,305 shares during the period. Shay Capital LLC purchased a new stock position in Xeris Biopharma during Q1 for approximately $34,000. Goldman Sachs Group Inc. increased its stake in Xeris Biopharma by 218.5% in the 1st quarter. Goldman Sachs Group Inc. now owns 725,255 shares of the company valued at $1,857,000 after purchasing an additional 497,564 shares in the last quarter. Finally, State Street Corp increased its stake in shares of Xeris Biopharma by 5.0% in the first quarter. State Street Corp now owns 384,761 shares of the company valued at $985,000 after acquiring an additional 18,252 shares in the last quarter. 18.72% of the shares are currently held by institutional investors and hedge funds.
XERS stock opened at $2.08 on Tuesday. Xeris Biopharma has a one-year minimum of $1.25 and a one-year maximum of $4.98. The company has a debt ratio of 1.43, a quick ratio of 2.42 and a current ratio of 2.67. The company’s fifty-day moving average price is $2.28 and its 200-day moving average price is $2.34. The company has a market capitalization of $138.31 million and a PE ratio of -1.41.
Xeris Biopharma Company Profile (Get a rating)
Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for endocrinology, neurology and gastroenterology patient populations. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycaemia; and Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proven to treat endogenous hypercortisolemia in adult patients with Cushing’s syndrome.
Get a Free Copy of Zacks Research Report on Xeris Biopharma (XERS)
For more information on Zacks Investment Research’s research offerings, visit Zacks.com
This instant news alert was powered by MarketBeat’s storytelling science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]
Should you invest $1,000 in Xeris Biopharma right now?
Before you consider Xeris Biopharma, you’ll want to hear this.
MarketBeat tracks daily the highest rated and most successful research analysts on Wall Street and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes hold…and Xeris Biopharma didn’t make the list.
While Xeris Biopharma currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
See the 5 actions here